

## AOP ID and Title:

AOP 460: Antagonist binding to smoothened causes disruption of shh signaling resulting in orofacial clefting

**Short Title: Antagonist binding to smoothened causes orofacial clefting**

## Authors

Jacob I. Reynolds<sup>1</sup>, Brian P. Johnson<sup>1,2</sup>

<sup>1</sup>Department of Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI

<sup>2</sup>Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI

## Status

### Author status

### OECD status

### OECD project

### SAAOP status

Under development: Not open for comment. Do not cite

## Summary of the AOP

## Events

### Molecular Initiating Events (MIE), Key Events (KE), Adverse Outcomes (AO)

| Sequence | Type | Event ID | Title                                                     | Short name                     |
|----------|------|----------|-----------------------------------------------------------|--------------------------------|
| 1        | MIE  | 2027     | <a href="#">Antagonism, Smoothened receptor</a>           | Antagonism Smoothened          |
| 2        | KE   | 2028     | <a href="#">Decrease, GLI1/2 translocation to nucleus</a> | Decrease, GLI1/2 translocation |

## Key Event Relationships

There are no Relationships associated with this AOP

## Stressors

### Name Evidence

Vismodegib High

## Vismodegib

Vismodegib (GDC-0449) is small molecule modulator of the sonic hedgehog (shh) pathway. It functions as an antagonist by binding to Smoothened (SMO) blockings its' activation and subsequent downstream signalling cascade. Vismodegib became the first agent approved to target the shh pathway in Jan. 2012 by the US FDA. It was approved by the European Medicines Agency (EMA) in July 2012 (Meiss, Andrllová et al. 2018). It has been used to identify critical periods of development for the shh pathway. Pregnant C57BL/6J mice dosed with 40mg/kg of Vismodegib between E7 and E10.0 had a peak incidence of CPO (34.38%) at E9.5 (Heyne, Melberg et al. 2015). Pregnant C57/BL6J mice treated with 100mg/kg vismodegib via oral gavage at E10.5 and E12.5 displayed a 100% penetrance of complete cleft palate (Zhang, Wang et al. 2017). In a HWJSC/HPEKp spheroid fusion model 10µm vismodegib did not affect HPEKp viability or migration, did not affect *in vitro* fusion (Belair, Wolf et al. 2018).

## Overall Assessment of the AOP

## References

## Appendix 1

### List of MIEs in this AOP

[Event: 2027: Antagonism, Smoothened receptor](#)

**Short Name: Antagonism Smoothened**

**AOPs Including This Key Event**

| AOP ID and Name                                                                                                               | Event Type               |
|-------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| <a href="#">Aop:460 - Antagonist binding to smoothened causes disruption of shh signaling resulting in orofacial clefting</a> | MolecularInitiatingEvent |

**Biological Context**

**Level of Biological Organization**

Molecular

**List of Key Events in the AOP**

[Event: 2028: Decrease, GLI1/2 translocation to nucleus](#)

**Short Name: Decrease, GLI1/2 translocation**

**AOPs Including This Key Event**

| AOP ID and Name                                                                                                               | Event Type |
|-------------------------------------------------------------------------------------------------------------------------------|------------|
| <a href="#">Aop:460 - Antagonist binding to smoothened causes disruption of shh signaling resulting in orofacial clefting</a> | KeyEvent   |

**Biological Context**

**Level of Biological Organization**

Molecular

## Appendix 2

**List of Key Event Relationships in the AOP**

There are no Relationships associated with this AOP